Magnesium L-Threonate for Focus and Memory: Why We Use Glycinate Instead, For Now

Short answer: Magnesium L-threonate (sold under the branded ingredient name Magtein) is marketed specifically on a cognition claim that magnesium glycinate never makes: that it crosses the blood-brain barrier more efficiently than other magnesium forms, raising brain magnesium levels and supporting memory and focus. That claim started with a real, well-known 2010 MIT/Tsinghua rat study, and it now has two human trials behind it — one small and directly funded and written by the compound's patent holder, one larger and more rigorous but still tied to the ingredient's commercial backers. Proco currently sells magnesium as glycinate, not threonate. That's not a dismissal of threonate's research — it's an honest read of where each form's evidence actually stands today. Glycinate has a broader, more independent evidence base for sleep and nervous-system regulation, plus decades of absorption research behind the glycine-bound form itself. Threonate's cognition claim is real, early, and worth watching — not yet worth building a product around. Here's the actual research behind that decision, ingredient by ingredient, trial by trial.

Evidence reviewed: September 2026.

The claim competitors are making, specifically

If you've shopped for a "brain-focused" magnesium, you've likely seen magnesium L-threonate marketed under the branded ingredient name Magtein — licensed by its patent holder to dozens of nootropic and cognitive-support brands. The pitch is narrower and more specific than most magnesium marketing: not "supports relaxation" or "supports sleep," but that threonate is the one magnesium form that meaningfully raises magnesium levels inside brain tissue, because the threonate molecule crosses the blood-brain barrier more efficiently than the compounds other magnesium forms (glycinate, citrate, oxide) are bound to.

That's a mechanistic claim, and it's a different one from what we look at when we evaluate magnesium glycinate for Magnesium Glycinate — glycinate's case rests on gut absorption and tolerability, not brain penetration. Threonate is playing a different game entirely, aimed squarely at focus and memory rather than sleep and calm. It deserves its own look on those terms, separate from the general glycinate-vs-citrate-vs-threonate comparison we've already published.¹

Where the claim actually comes from: a 2010 rat study

The blood-brain-barrier story isn't marketing invention — it traces to a real, peer-reviewed study. In 2010, a team led by Guosong Liu, working across MIT and Tsinghua University's Center for Learning and Memory (in a lab that included Nobel laureate Susumu Tonegawa as a co-author), published a study in Neuron testing whether raising brain magnesium could improve learning and memory.² Using magnesium-L-threonate (MgT) in rats, the researchers found it elevated brain magnesium levels, increased synaptic density and plasticity in the hippocampus, and improved spatial and associative memory in both young and aged rats.²

A compound that elevates brain magnesium and improves memory in rats is a genuinely promising starting point — it is not the same claim as it doing the same thing, at the same scale, in you.

That distinction matters because it's the actual sequence of events: an animal study established a real, mechanistically interesting effect, and a specific magnesium compound — magnesium-L-threonate — was patented around it by Liu's company, Neurocentria, Inc. The commercial product built on this research is what's now licensed to other brands as Magtein.³ None of that makes the rat data less real. It does mean the next question — does it work the same way in people — needed its own, separate evidence, funded independently of the people who hold the patent.

The first human trial: promising, small, and written by the patent holder

The first published human trial of magnesium-L-threonate for cognition came in 2016, from the same Guosong Liu, in the Journal of Alzheimer's Disease.⁴ It's worth knowing exactly what it did and didn't show:

Those are real, statistically significant results in a real randomized, placebo-controlled trial. But two things temper how much weight they should carry. First, the size: 44 completers is a small trial by any standard, especially for a claim this specific. Second, and more important: the study states plainly that it "was funded by Neurocentria Inc.," the compound's patent holder, and that Neurocentria conducted the statistical analysis and wrote the paper.⁴ That's not a reason to throw the result out — trials funded by an ingredient's owner can still be real science — but it's a conflict of interest worth knowing before treating this as independent confirmation. An analysis run and written by the company that profits from a positive result is a different evidentiary standard than an independently funded replication.

The newer trial: bigger, better-designed, still industry-adjacent

A second, more recent trial addresses some of that first study's weaknesses. Published in Frontiers in Nutrition in January 2026, Lopresti and Smith ran a randomized, double-blind, placebo-controlled trial in 100 adults aged 18–45 with self-reported poor sleep, over 6 weeks.⁵ This is a larger sample than the 2016 trial, in a broader (younger, non-clinical) population, testing both cognition and sleep outcomes:

That's a genuinely mixed result, reported honestly by the study itself: a significant effect on one composite measure and on working memory, no effect on a separate reasoning test, and no effect on objectively measured sleep despite self-reported improvement. This is a more credible design than the 2016 trial — bigger sample, cleaner outcome reporting — and it's also not a clean sweep. On independence: the ingredient used in the trial is manufactured by ThreoTech and distributed by AIDP under the Magtein brand, and industry trade press covered the results enthusiastically alongside quotes from Magtein's own team the same week it published.⁶ That doesn't make the trial's data wrong. It does mean two of the three human data points behind this ingredient's cognition claim — the original small trial and the surrounding commercial response to the larger one — come from parties with a direct financial stake in a positive result. That's a meaningfully different evidentiary position than an ingredient with multiple independently replicated trials behind it.

Why we ship glycinate, not threonate — for now

We're not ruling threonate out. The mechanism has real rat data behind it, and the newer human trial is a step up from the first. But three things keep it out of Proco's range today, honestly stated:

1. The evidence base is thinner and younger than glycinate's. Glycinate's case rests on absorption and tolerability data going back to the 1990s, replicated across independent research groups with no single company controlling the underlying patent, plus a 2025 independent sleep trial showing real, if modest, benefit.¹ Threonate has one small industry-run trial and one larger, more credible trial that's still commercially adjacent. Neither situation is disqualifying on its own — but glycinate's total evidence weight is heavier and more independent today.

2. Proco's current sleep and nervous-system formulas are built around glycinate's use case, not threonate's. Magnesium Glycinate is positioned for sleep and nervous-system regulation, where its evidence is strongest. Threonate's claim is specifically cognitive — closer in spirit to Cognitive Support's territory than to a magnesium single-ingredient product built for winding down at night. Adding it well would mean building (or evaluating) it as a focus-and-memory ingredient, not slotting it in as "another magnesium."

3. We'd rather wait for independent replication than launch on trade-press momentum. The Lopresti trial is a real step forward, but one larger trial connected to an ingredient's commercial distributor isn't the same evidentiary bar as multiple independently funded replications. This is the same posture we've taken with other ingredients under consideration but not yet added to the range — the honest answer is "not yet," not "no."

If you specifically want the mechanism threonate is chasing — a magnesium form aimed at cognition rather than sleep — the most honest thing we can tell you today is that the early human evidence is real but not yet independently confirmed at scale. If your goal is sleep, stress, or general nervous-system support, glycinate's evidence is the stronger, more established case, which is exactly why it's what we sell. For the deeper dive on why glycinate specifically — separate from this cognition-focused threonate question — see our full form-by-form comparison.¹

Bottom line

Threonate's cognition story isn't manufactured — it started with legitimate mechanistic research and now has real, if early and commercially-adjacent, human trial support. That's a meaningfully different position from an ingredient with no science behind it at all. It's also not yet the kind of independently replicated evidence base that glycinate has for its own use case. We'd rather tell you honestly where that line sits than blur it either direction — overselling threonate's readiness, or pretending the rat and trial data don't exist.

This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.

References

1. "Magnesium Glycinate vs. Citrate vs. Threonate: Which Form for Sleep, Stress, or Focus?" Proco. procohq.com
2. Slutsky I, Abumaria N, Wu LJ, et al. "Enhancement of Learning and Memory by Elevating Brain Magnesium." Neuron, 2010. pubmed.ncbi.nlm.nih.gov
3. Neurocentria, Inc. Patent portfolio, magnesium threonate compositions and methods of use. patents.justia.com
4. Liu G, Weinger JG, Lu ZL, Xue F, Sadeghpour S. "Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial." Journal of Alzheimer's Disease, 2016. pubmed.ncbi.nlm.nih.gov
5. Lopresti AL, Smith SJ. "The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial." Frontiers in Nutrition, 2026. frontiersin.org
6. "Magtein magnesium L-threonate may boost cognitive performance and improve sleep." NutraIngredients, 2026. nutraingredients.com

Related reading: Magnesium Glycinate vs. Citrate vs. Threonate and Magnesium Glycinate: Why This Form, and What the Absorption Evidence Shows.

Want to know what's actually in what you take? Join the list — no spam, just it straight.